In addition, we have recently provided comprehensive evidence for the therapeutic potential of targeting the peripheral CB1R for the treatment of obesity, T2D, NAFLD, chronic kidney disease, and osteoporosis [[26], [27], [28], [29], [30], [31], [32], [33], [34]]. Here, CNR1 is linked to metabolic dysfunction-associated steatotic liver disease.